Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis

References

• Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990;322:1277–1289.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–2219.
   PubMed Web of Science ®Google Scholar
• Ehrchen JM, Sunderkotter C, Foell D, et al. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86:557–566.
   PubMed Web of Science ®Google Scholar
• Perera C, McNeil HP, Geczy CL. S100 Calgranulins in inflammatory arthritis. Immunol Cell Biol. 2010;88:41–49.
   PubMed Web of Science ®Google Scholar
• Abildtrup M, Kingsley GH, Scott DL. Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. J Rheumatol. 2015;42:760–770.
   PubMed Web of Science ®Google Scholar
• Centola M, Cavet G, Shen Y, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013;8:e60635.
   PubMed Web of Science ®Google Scholar
• Acar A, Guzel S, Sarifakioglu B, et al. Calprotectin levels in patients with rheumatoid arthritis to assess and association with exercise treatment. Clin Rheumatol. 2016;35:2685–2692.
   PubMed Web of Science ®Google Scholar
• Choi IY, Gerlag DM, Herenius MJ, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:499–505.
   PubMed Web of Science ®Google Scholar
• Garcia-Arias M, Pascual-Salcedo D, Ramiro S, et al. Calprotectin in rheumatoid arthritis: association with disease activity in a cross-sectional and a longitudinal cohort. Mol Diagn Ther. 2013;17:49–56.
   PubMed Web of Science ®Google Scholar
• Andrés Cerezo L, Mann H, Pecha O, et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2011;13:R122.
   PubMed Web of Science ®Google Scholar
• Chen YS, Yan W, Geczy CL, et al. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther. 2009;11:R39.
   PubMed Web of Science ®Google Scholar
• De Seny D, Fillet M, Ribbens C, et al. Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin Chem. 2008;54:1066–1075.
   PubMed Web of Science ®Google Scholar
• Hammer HB, Odegard S, Fagerhol MK, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis. 2007;66:1093–1097.
   PubMed Web of Science ®Google Scholar
• Sunahori K, Yamamura M, Yamana J, et al. The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther. 2006;8:R69.
   PubMed Web of Science ®Google Scholar
• De Rycke L, Baeten D, Foell D, et al. Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J Pathol. 2005;206:17–27.
   PubMed Web of Science ®Google Scholar
• Drynda S, Ringel B, Kekow M, et al. Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFalpha therapy. Pathol Res Pract. 2004;200:165–171.
   PubMed Web of Science ®Google Scholar
• Madland TM, Hordvik M, Haga HJ, et al. Leukocyte protein calprotectin and outcome in rheumatoid arthritis. A longitudinal study. Scand J Rheumatol. 2002;31:351–354.
   PubMed Web of Science ®Google Scholar
• Burmeister G, Gallacchi G. A selective method for determining MRP8 and MRP14 homocomplexes and heterocomplexes by sandwich ELISA for the discrimination of active and non-active osteoarthritis from rheumatoid arthritis in sera and synovial fluids. Inflammopharmacology. 1995;3:221–230.
   Google Scholar
• Brun JG, Jonsson R, Haga HJ. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. J Rheumatol. 1994;21:733–738.
   PubMed Web of Science ®Google Scholar
• Brun JG, Haga HJ, Bøe E, et al. Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity. J Rheumatol. 1992;19:859–862.
   PubMed Web of Science ®Google Scholar
• Berntzen HB, Fagerhol MK, Ostensen M, et al. The L1 protein as a new indicator of inflammatory activity in patients with juvenile rheumatoid arthritis. J Rheumatol. 1991;18:133–138.
   PubMed Web of Science ®Google Scholar
• Berntzen HB, Munthe E, Fagerhol MK. The major leukocyte protein L1 as an indicator of inflammatory joint disease. Scand J Rheumatol Suppl. 1988;76:251–256.
   PubMedGoogle Scholar
• Song GG, Lee YH. Comparison of disease activity score 28 using C-reactive protein and disease activity score 28 using erythrocyte sedimentation rate in assessing activity and treatment response in rheumatoid arthritis: a meta-analysis. J Rheum Dis. 2016;23:241–249.
   Google Scholar
• Kang KY, Woo JW, Park SH. S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis. Korean J Intern Med. 2014;29:12–19.
   PubMed Web of Science ®Google Scholar
• Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
   PubMedGoogle Scholar
• Ridout KK, Ridout SJ, Price LH, et al. Depression and telomere length: A meta-analysis. J Affect Disord. 2016;191:237–247.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): L. Erlbaum Associates; 1988.
   Google Scholar
• Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315:1533–1537.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol. 2007;26:201–204.
   PubMed Web of Science ®Google Scholar
• Hammer HB, Haavardsholm EA, Kvien TK. Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis. Scand J Rheumatol. 2008;37:179–182.
   PubMed Web of Science ®Google Scholar
• Hammer HB, Odegard S, Syversen SW, et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:150–154.
   PubMed Web of Science ®Google Scholar
• Inciarte‐Mundo J, Victoria Hernández M, Ruiz‐Esquide V, et al. Serum Calprotectin Versus Acute‐Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors. Arthritis care & research. 2016;68:899–906.
   PubMed Web of Science ®Google Scholar
• Inciarte-Mundo J, Ruiz-Esquide V, Hernández MV, et al. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology. 2015;54:2239–2243.
   PubMed Web of Science ®Google Scholar
• Hurnakova J, Zavada J, Hanova P, et al. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17:252.
   PubMed Web of Science ®Google Scholar
• Nordal HH, Brokstad KA, Solheim M, et al. Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis. Arthritis Res Ther. 2017;19:3.
   PubMed Web of Science ®Google Scholar
• Hurnakova J, Hulejova H, Zavada J, et al. Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. PLoS One. 2016;11:e0165498.
   PubMed Web of Science ®Google Scholar
• Bakker MF, Cavet G, Jacobs JW, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis. 2012;71:1692–1697.
   PubMed Web of Science ®Google Scholar
• Selby C. Interference in immunoassay. Ann Clin Biochem. 1999;36:704–721.
   PubMed Web of Science ®Google Scholar